CorestemChemon, Reorganized Stakeholders Set Stage for FDA Bid, With ALS Therapy Key

CorestemChemon largest shareholder Kyung-sook Kim’s stake fell from 13.89% to 10.89%, a decline of 3 percentage points. The change resulted from the blanket exclusion of 47,200 shares and exchangeable bonds convertible into 1,537,872 shares held by Kwang-soon Kwon, formerly a specially related party, from the holdings of specially related parties after Kwon stepped down as an inside director on Aug. 31. Because the change reflects a narrower scope of related parties rather than a stake sale, its implications for corporate governance warrant separate consideration.

According to the Financial Supervisory Service’s Electronic Disclosure System (DART), Kyung-sook Kim holds 5,758,137 CorestemChemon shares (10.89%) together with 12 specially related parties. Compared with 7,343,209 shares (13.89%) in the previous report, dated April 1, the total declined by 1,585,072 shares. Kim’s own holdings were unchanged at 3,431,025 shares (6.49%). Among the specially related parties, CEO Gil-an Yang holds the largest stake, with 1.2 million shares (2.27%).

The collateral agreement is a point of particular interest. Kim entered into an agreement with Moon & Polaris to provide 1 million voting shares (1.89%) as collateral. The loan amount is 5 billion won, with an annual interest rate of 6%. For minority shareholders, a structure in which the largest shareholder raises funds using the stake as collateral warrants close attention because a sharp decline in the share price could lead to the forced sale of the collateral.

Neuronata-R turns to subgroup data to knock on FDA’s door

CorestemChemon was launched in December 2022 through the merger of Corestem, a company specializing in stem cell therapies, and Chemon, a contract research organization (CRO) for preclinical and clinical trials. Its key pipeline is Neuronata-R, an autologous stem cell therapy for amyotrophic lateral sclerosis (ALS). The therapy failed to meet the primary endpoint in the overall patient population in the phase 3 ALSummit trial. However, among patients with slower disease progression (Slow Progressors), the combined assessment of function and survival (CAFS) improved statistically significantly versus placebo in both the two-dose group (20.95 vs 13.66, p<0.024) and the five-dose group (24.78 vs 17.92, p<0.041).

The company plans to use the subgroup data, together with data showing reductions in levels of the nerve injury biomarker neurofilament light chain (NfL), as the basis for seeking accelerated approval from the FDA. NfL is the biomarker the U.S. FDA used as a criterion for the accelerated approval of the ALS therapy tofersen, and a consistent downward trend was observed in the Neuronata-R treatment group. CorestemChemon plans to pursue a Type C meeting with the FDA and is targeting accelerated approval through a biologics license application (BLA). Real-world data (RWD) accumulated from records of more than 400 patients treated since the conditional approval by Korea’s Ministry of Food and Drug Safety in 2014 will also be an asset in this process.

In mid-2026, Korea’s Ministry of Food and Drug Safety approved a change to Neuronata-R’s product labeling, narrowing the indication to patients with slow disease progression, rather than revoking its conditional approval. This is viewed as an example of regulators responding flexibly to rare diseases with high unmet medical needs. However, obtaining accelerated approval from the FDA based on subgroup data from a trial that failed to meet its overall endpoint is a separate issue. Some in South Korea’s biotechnology industry have expressed caution, saying, “Even with abundant Korean real-world data, clearing the FDA’s threshold for accelerated approval will be a difficult challenge.”

Monetizing CRO business represents another growth pillar

CorestemChemon built a cell-processing and manufacturing facility in Osong, North Chungcheong province, that meets both Korea’s Ministry of Food and Drug Safety and the U.S. FDA’s commercial good manufacturing practice standards. It also established a commercialization base in the United States by becoming the first South Korean company to join the North Carolina Regenerative Medicine Engine project, supported by the U.S. National Science Foundation (NSF). In its CRO business, the company is pursuing the commercialization of a transcriptome analysis and organoid-based preclinical testing platform through a partnership with ATG Lifetech. The global preclinical CRO market is projected to grow at an average annual rate of 12.7% from approximately $8.79 billion in 2024, while organoid-based analysis is considered capable of improving the accuracy of toxicity and efficacy predictions by up to fivefold compared with conventional 2D cell culture.

Ultimately, the latest change in shareholdings can be read as part of a management reorganization. Kwang-soon Kwon’s departure reduced the scope of specially related parties, bringing CEO Gil-an Yang’s leadership structure to the forefront. The likelihood of FDA approval for Neuronata-R and the pace of monetization of the CRO business will be key variables determining the stock’s future direction, with the market expected to focus closely on the fate of the 1 million shares pledged as collateral.